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Cyrus P. Adams-Mardi: Does the Gut Microbiota Influence the Immune Response to Influenza 
Vaccination in Obese Populations? 
(Under the Direction of Melinda Beck) 
In the United States and globally, rates of obesity have greatly increased and prevalence is 
continuing to grow. As of 2014, 35.0% of adult males and 40.4% of adult females in the U.S. were 
obese, according to the National Health and Nutrition Examination Survey (NHANES).1 Previous 
research in the Beck lab has demonstrated that vaccinated obese individuals have twice the 
likelihood of developing influenza or “flu-like-illness” when compared to healthy weight 
individuals, despite antibody levels above the threshold of protection.2 This is concerning because 
the influenza vaccination is the single most effective method of protection. What is not understood 
is the mechanisms underlying this difference in obese individuals. Previous work in the Beck Lab 
has found that antibody response is not significantly different between obese and lean individuals 
30 days post vaccination, but falters between that time and one-year post vaccination. We have 
also found that there is a difference in the metabolism and function of T cells in the response to 
the influenza vaccination. With the goal of discovering new research directions that might aid in 
the discovery of molecular mechanisms underlying this phenomenon, I conducted a study using a 
bioinformatics approach to analyze the gut microbiota as a potential mediator. Strong preliminary 
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CHAPTER I - INTRODUCTION 
Obesity  
 In the United States and globally, rates of obesity have greatly increased and prevalence is 
continuing to grow. As of 2014, 35.0% of adult males and 40.4% of adult females in the U.S. were 
obese, according to the National Health and Nutrition Examination Survey (NHANES).1 
Overweight and obesity are defined using the body mass index (BMI), a measure that incorporates 
both height and weight. BMI is reported using the formula weight (kg)/ height (m2). Not only is 
over a third of the U.S. obese (BMI ≥ 30 kg/m2), but over two thirds of the U.S. population is either 
overweight or obese (BMI ≥ 25 kg/m2).3 In the year 2000, 15% of total deaths in the U.S. were 
attributed to excess weight stemming from poor diet and low physical activity.4 Further, a 2019 
publication by Afshin et al. showed that poor diets are responsible for more deaths globally (1990-
2017) than any other risk factor, including smoking.5 
This is a complex problem due to the multifactorial web of risk factors that contribute to 
the obesity epidemic. Behavioral, environmental, and genetic factors all must be considered in 
addressing this broad public health crisis. In particular, the effects of increased caloric 
consumption and decreased daily physical activity that has come to define global trends in 
industrialized countries is an active area of research. The CDC reports that less than half of adults 
in the U.S. meet basic recommended physical activity requirements of 30 minutes of exercise per 
day, 4 days a week.6 This paradigm is further complicated by the fact that poverty is no longer 
associated with low body weight, but rather with obesity due to the affordable nature of unhealthy 
calorically dense and processed foods.6 Obesity has increased in prevalence in all age groups, 
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races, and genders which raises concern for future trajectories of global health.4 However, it must 
be noted that disparity exists in the races most affected by obesity. The proportion of Hispanic and 
African American individuals in the U.S. who are affected by obesity is significantly higher than 
that of other ethnicities such as Caucasians and Asian Americans.7 The U.S. has the highest rates 
of obesity in the world, and there is a concerning increase in the prevalence of childhood obesity 
which places future generations at risk of health complications as well.7 
Obesity is caused by increased energy intake and decreased energy expenditure that results 
in sustained positive energy balance and the accumulation of excess adipose tissue.8 Increased 
visceral adiposity in the abdomen, a key feature of obesity, is associated with metabolic 
perturbations that extend beyond the physical phenotype of increased adipose tissue. Visceral 
adipocytes are metabolically impaired in obesity and release increased amounts of pro-
inflammatory cytokines in response to the abnormal surplus of lipid stores in the abdominal 
cavity.8  This in turn recruits increased numbers of immune cells, which then secrete pro-
inflammatory mediators as well.8 These cytokines, including but not limited to TNFα (tumor 
necrosis factor alpha) and IL-6 (interleukin-6), expose other tissues to a higher level of 
inflammatory stimulation in obese individuals compared to those who are lean.8 These signals 
cause systemic activation of other inflammatory pathways including but not limited to JNK (c-jun 
N-terminal kinase), inflammasome, and PRR (pattern recognition receptor) mechanisms.8 This 
indicates that obesity is associated with a variety of conditions related to low-grade chronic 
inflammation, in addition to hormonal and metabolic dysfunction as a result.8  
Chronic conditions such as metabolic syndrome, type II diabetes mellitus, cardiovascular 
disease, renal disease, and cancer are all associated with obesity.8 Metabolic syndrome is an 
assortment of risk factors for cardiovascular disease (CVD) risk and diabetes. Comorbidity with 
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three of the five following factors results in a diagnosis of metabolic syndrome: hyperglycemia, 
elevated blood pressure, elevated serum triglyceride levels, low high-density lipoprotein 
cholesterol levels, and obesity (particularly central adiposity).9 Recently, there has also developed 
a growing body of research suggesting that the risk of disease in obesity extends beyond just 
chronic conditions.3,10  
Obesity has been shown to increase both the incidence of, and the risk associated with, 
infectious diseases.3,10 The course of bacterial infections is altered in obesity according to previous 
cohort studies and systematic reviews.11 Additionally, obesity appears to contribute to the overall 
development and progression of chronic viral infections such as hepatitis C.12 Acute viral 
infections are also riskier in obesity. H1NI influenza infections that result in hospitalization, 
intensive care treatment, or death have a common significant comorbidity of obesity.10 Notably, 
obesity is linked to impairment of the immune response to influenza virus and influenza 
vaccination as well.2,3,13–18  
Influenza Virus and the Immune System 
 A complex system of cellular and secreted components, the competence of the immune 
system is affected by a variety of factors. The innate and adaptive arms of the immune system 
work in conjunction to combat new and previously encountered pathogens. The innate arm of the 
immune system responds to pathogens with uniform cellular, molecular, and physical mechanisms. 
The adaptive arm utilizes the processes of genetic recombination via somatic hypermutation, and 
affinity maturation to create pathogen-specific antibody secreting (Plasma cells) lymphocytes, 
cytotoxic lymphocytes (CD8+ T cells or CTLs), or helper lymphocytes (CD4+ T cells or Th cells). 
In addition to these effector cells, adaptive immunity also creates long-lasting memory T and B 
lymphocytes that, upon activation, will undergo rapid differentiation to specific effector cells to 
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create a response that is faster and higher in magnitude to subsequent exposures to the same 
pathogen. Functioning properly, the immune system can recognize and eliminate pathogens 
without the host having any symptoms that typically characterize the infection. However, 
dysfunction in either arm of the immune system can put the host at risk for greater susceptibility 
to infection. The influenza virus is a good example of a pathogen that affects people very 
differently based on a variety of risk factors such as age and BMI. 
 Influenza, an RNA virus, contains 8 single stranded RNA segments. The influenza virus 
has a spherical shape with an outer layer that contains hemagglutinin (HA) and neuraminidase 
(NA) glycoproteins. These proteins are used in the naming system for all influenza viruses (i.e. 
H1N1 contains hemagglutinin type 1 and neuraminidase type 1), and are typically targeted in 
influenza vaccines and targeted by influenza specific antibodies.19 HA functions for attachment to 
host cell receptors and NA involves releasing new virus from the host cell. There are 16 known 
HA and 9 known NA proteins that lend to the wide diversity of influenza strains that have been 
isolated throughout history.20 All strains of influenza are not infectious to all organisms, only 
certain types of influenza can infect humans, and some can infect multiple species (i.e. historical 
pandemic swine or avian influenza which did not originate in humans).  
 Influenza infects millions of people annually across the globe, and is a significant cause of 
death in elderly populations. The virus itself infects cells by first binding HA to sialic acid cell 
surface receptors on the host plasma membrane. The virus is engulfed by the host cell where it its 
RNA is translated to viral protein using host ribosomes and amino acids. The virus then exits the 
cell by crossing the membrane using a process referred to a viral budding. The process of viral 
budding is such that after production in the host cell, the HA and NA proteins are associated in the 
host cell membrane.19 This induces a curvature to the surface of the membrane, forming what is to 
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become the outer surface of the viral particle. The viral RNA is then packaged inside the envelope 
proteins and the influenza virus buds out of host cell. This means that the viral surface is actually 
constructed from the hosts very own plasma membrane.19 
 Antigen presenting cells (APCs - dendritic cells and macrophages) are the first immune 
cells to come into contact with the influenza virus if it successfully penetrates the mucous layer 
and epithelial junctions in the respiratory tract, as influenza is an airborne virus. APCs are 
phagocytic and will engulf and digest the viral particle upon pathogen recognition. They will then 
present fragments of viral peptide (antigens) on their surface combined with MHC (major 
histocompatibility complex) class I and class II.21 After migrating to secondary lymphoid tissues 
such as draining lymph nodes or the spleen, the MHC class I and II bound antigens are presented 
to the adaptive immune cells, T and B lymphocytes. Upon contact with a naïve adaptive 
lymphocyte that has not encountered antigen and differentiated, the APC will initiate adaptive 
immunity by receptor recombination via somatic hypermutation and affinity maturation to the 
presented antigen.21 
The process of somatic recombination will induce antibody production (humoral response) 
by plasma cells differentiated from antigen-specific B cells, cytotoxic CD8+ T cell (cellular 
immunity) response, and helper CD4+ T cell response (cellular immunity). It will also trigger the 
differentiation of memory T and B cells that are metabolically programmed with survival signals 
that are designed so that the cell lives long enough to initiate a proper response to a potential re-
exposure to the antigen. Cytotoxic T cells and helper T cells are mainly differentiated to respond 
to more conserved regions of the viral particle and are therefore more responsive to a variety of 
influenza subtypes within influenza A for example, compared to B cell responses.21 CTLs are 
responsible for the killing of virally infected cells upon recognition and rely on granzymes (GrA, 
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GrB) for this lytic activity.21 Th cells are responsible for helping B cells secrete antibodies, 
secreting cytokines that enhance macrophages phagocytosis, and activating cytotoxic T cells to 
kill virus-infected cells.21  
The primary immunoglobulin secreted from plasma cells is IgG. There are 4 subclasses of 
IgG: IgG1, IgG2, IgG3, and IgG4 which are in order of decreasing abundance.22 IgG1 is typically 
part of the humoral response to protein antigens.22 IgG2 is effective in response to carbohydrate 
antigens such as capsular polysaccharides.22 IgG3 antibodies are best known for their pro-
inflammatory function as inducers of effector function.22 IgG4 is known to be induced in response 
to allergens and long-term non-infectious antigen exposure.22 IgG1, IgG2, and IgG3 commonly 
induced in response to acute infections and vaccination and are of particular interest. Clearly, both 
arms of the immune system are crucial for this response and. After the infection has been 
controlled, approximately 90% of effector cells then undergo apoptosis and about 10% of the 
effector population with specificity transition to the aforementioned T and B memory cells. 
Influenza specific antibodies will also continue circulating, which can flag viral particles for 
destruction even after the plasma cells stop secreting, as the antibodies outlive the plasma cells for 
a short period of time. 
In order to discuss the role of obesity in this complex mechanism, it is important to discuss 
the landmark 2011 paper about the 2009 California influenza A pandemic. This paper was one of 
the first of its kind to establish obesity as an independent risk factor for contracting influenza and 
having more severe outcomes to influenza infection.3 In this multivariate analysis which controlled 
for other risk factors for severe influenza outcomes, the investigators used public health 
surveillance data to determine that extreme obesity (having a BMI ≥ 40 kg/m2) was significantly 
associated with death in response to influenza infection.3 This was groundbreaking in public health 
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because the 2009 pandemic was responsible for hundreds of thousands of deaths worldwide.3 With 
the rising burden of obesity globally that was being lead by the U.S., this became a critical need 
for further research because it meant that more obese countries could be more vulnerable to 
outbreaks of pandemic influenza.  
Antigenic drift in the influenza virus is the mild level of annual change in the virus that 
results in seasonal outbreaks globally. Antigenic shift however, is a big and impactful change due 
to mutation and combination from multiple strains of virus which typically results in pandemic 
outbreaks. These two factors together ensure that the flu is a constant burden of disease. It is 
important to note that even though the flu season is typically worse from late fall to early spring, 
it is a year-round risk as summer outbreaks can occur too. In addition, the seasonal difference 
between the northern and southern hemispheres means that while it is summer in one half of the 
world, it is flu season in the other. The lack of seasonal variability in equatorial regions means that 
there is a relatively constant baseline level of influenza activity year round without seasonal 
cycling. That is why it is particularly important to keep up to date with the influenza vaccination 
if traveling between hemispheres. The risk is compounded by the wide variety of individuals who 
are especially susceptible to severe flu outcomes, including young children, the elderly, pregnant 
women, the immunocompromised, asthma, chronic pulmonary disease, and chronic cardiovascular 
disease in addition to those with obesity.3 In counteracting this public health threat, the influenza 
vaccination is the single most effective intervention for flu protection. 
Obesity and Influenza Vaccine 
 Previous research in the Beck lab has demonstrated that vaccinated obese individuals have 
twice the likelihood of developing influenza or “flu-like-illness” when compared to healthy weight 
individuals, despite antibody levels above the threshold of protection.2 Although it appears as 
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though a diminished antibody response is likely not the cause of increased risk of influenza in 
obese adults, the T cell response to the vaccine is impaired. Compared with lean adults, T cells 
from obese adults stimulated with vaccine strains of virus are less functional and less activated. 
Thus, it is likely that impaired T cell responses in obese adults results in increased susceptibility 
to influenza, despite vaccination. However, the mechanisms underlying T cell impairment are not 
clear.13 
 The typical influenza vaccination is trivalent (TIV, trivalent influenza vaccination) which 
means that it contains three inactivated forms of influenza. There have also been quadrivalent 
forms which contain 4 inactivated forms of influenza. The trivalent vaccine contains two A strains 
and a B strain, while the quadrivalent vaccine contains two type A strains and two type B strains 
of inactivated influenza virus. Though this assortment does not differ between vaccination years, 
the change is within the influenza A and B subtypes. The vaccination is now available in 
inactivated and live-attenuated versions, but the inactivated form is still the most popular because 
the live-attenuated vaccine is associated with higher amounts of post-vaccination viral shedding 
from the nasal mucosa due to its intranasal route of administration, as opposed to the standard 
intramuscular injection to the deltoid muscle. The WHO has a global network of reporting 
locations for isolated strains, and analyzes which strains annually should be included in the 
vaccination. The virus strains to be included in the split vaccine are grown in embryonated chicken 
eggs, extracted from the allantonic fluid, disrupted with a detergent, and combined in the final 
immunization. The vaccine stimulates immunological memory, which means that those who 
receive it will have a fast and robust adaptive response to an influenza virus if it is protected against 
either by inclusion in the year’s vaccine or by cross-protection.  
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 The immune system’s mechanism of response to the influenza vaccination is almost 
identical to that against the influenza virus, as the vaccination is targeted to this pathway. The 
deltoid muscle, for example, is selected for because of its high concentration of dendritic cells (an 
APC) that will present the viral fragments and migrate to lymphoid tissues. Vaccination induces a 
memory response. This means that, when exposed to virus, plasma cells will more quickly produce 
larger amounts of specific antibody (primarily IgG), and CD4+ and CD8+ Th and CTL T cells will 
respond faster and more robustly by secreting inflammatory cytokines.  
 Previous research in the Beck Lab has investigated the mechanistic underpinnings of the 
findings of the 2011 publication on the increased risk of death and complications form flu in the 
2009 California pandemic associated with obesity. In a 2012 study, Sheridan et al. determined that 
obese adults showed no impairment in the antibody response to the trivalent influenza vaccination 
measured at one-month post-vaccination.13 This finding indicated that the problem with the 
vaccination response was not due to malfunctioning B cells. It was discovered, however, that this 
antibody response was not sustained one-year post vaccination, and that obese vaccinated 
individuals had a significantly lower antibody response compared to lean vaccinated individuals.13 
In subsequent research by Neidich et al., it was demonstrated that obese adults were less protected 
from infection (had twice the risk of influenza or flu-like illness) than those who were lean, despite 
vaccination and antibody levels that did not differ significantly from non-obese individuals.2 
Neither seroconversion nor seroprotection in response to influenza differed significantly between 
obese and healthy weight individuals.2 Both of these are measures of hemagglutination inhibition 
assays (HAIs). Seroconversion is a 4-fold increase in flu-specific antibody titer after vaccination, 
while seroprotection is an HAI titer above 40 (expressed as a concentration at which 
hemagglutination is inhibited between flu HA and turkey erythrocyte sialic acid receptors). This 
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result indicates that some other components of the immune system might be the cause and not the 
humoral response. 
 An investigation by Smith et al. showed that mice with diet-induced obesity had worse 
lung pathology, higher mortality, and significantly differed immune responses following infection 
with the influenza virus.16 Smith’s investigation showed that obese mice had diminished cytokine 
responses and reduced natural killer (NK) cell effector function in response to the influenza virus 
compared to lean mice.16 This is notable because the NK cell is a key component of the innate 
immunity that is specially armed to initiate apoptosis virally infected cells. T cells are also of 
particular interest and it has been hypothesized they could be the source of impairment in the 
response to the TIV in obesity.  
 Karlsson et al. found that mice with diet-induced obesity has significantly impaired T cell 
responses to the influenza infection.17 Twenty-five percent of obese mice in the study died after 
being exposed to the influenza virus, while none of the lean mice died after being exposed to the 
same virus.17 The obese mice were also found to have a significantly diminished proportion of 
influenza specific CD8+ T cells producing IFN-γ (interferon gamma) compared to lean mice.17 
Investigation by Paich et al. revealed that Th and CTL T cells were impaired in vaccinated obese 
individuals as well when compared to vaccinated lean individuals because they expressed less 
activation markers (CD28 and CD69) and functional markers (GrB and IFN-γ) in response to cell 
culture H1N1 influenza challenge.18 Granzyme B (GrB) is secreted by CD8+ cytotoxic T cells. It 
signals apoptotic cell death in target cells. Levels of granzyme B and IFN-γ are naturally elevated 




The Gut Microbiota as a Mediator of Obesity Impaired Vaccine Response 
 The perturbations seen in the inflammatory behavior of visceral adipocytes are not the only 
systemically impactful alterations that occur with obesity. The intestinal, or gut, microbiota is a 
current hot button of research because it is associated with disease states and can be modulated. In 
the past ten years there has been a frenzy of research published investigating the relationship 
between host obesity and the the microbial composition of the intestines. The gut microbiota is the 
population of microorganisms including bacteria, viruses, and fungi that colonize and inhabit the 
lower gastrointestinal tract.23 This is not to be confused with the commonly used, and often 
misused, term gut microbiome. The gut microbiome is the sum of the genetic materials of those 
organisms that make up the gut microbiota. The gut microbiota is often referred to as its own organ, 
in that it is physiologically “outside” of the human the body. The human gut microbiota is 
predominantly described by 5 phyla of bacteria: Bacteroidetes, Firmicutes, Actinobacteria, 
Proteobacteria, and Verrucomicrobia, with over 90% of the total bacterial species being in 
Firmicutes and Bacteroidetes.24 
The development of the gut microbiome begins in utero, but the first major colonization 
occurs at birth, and can even differ depending on the route of delivery.25 In the search for 
physiological targets of environmental predictors of health, the microbiota has emerged as an area 
of interest because has been found to both protect from and exacerbate disease depending on its 
composition.25 The composition of the gut microbiome has also been found to be altered in disease 
states and varies due to both endogenous and exogenous factors.26 The relationship between the 
host and the gut microbiota is generally symbiotic. The gut microbiota aid in the digestion of 
certain indigestible nutrients and aid in increasing the caloric yield of diet and increase short chain 
fatty acid availability.27 However, in certain states the gut microbiota can be associated with 
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chronic low grade inflammation as well.23 In a chronic pro-inflammatory state such as obesity, this 
could be a contributing factor to the underlying immune impairment we see with the influenza 
vaccine.  
In many studies obesity appears to be associated with an increase in Firmicutes and a 
decrease in Bacteroidetes in most research, but this finding has been increasingly contested in the 
advent of ongoing investigation.23 Techniques such as sequencing of the DNA encoding for the 
16S ribosomal RNA (rRNA) have allowed for further insight into perturbations of the gut 
microbiota that occur with different diets and obesity.23 There have also been contrasting findings 
in the effects of obesity on the diversity of the gut microbiota.28 Kasai et al. found that obese 
individuals in Japan had a greater gut microbial diversity compared to non obese individuals.29 
Conversely, Line et al. found that there was no difference in gut microbial diversity with BMI in 
Chinese adults.30 In order to address the lack of consistency in obesity and BMI related gut 
microbiota research, Finucane et al. conducted an investigation that showed that the inter-study 
variation in gut microbiota far exceeds significant differences found between lean and obese 
individuals within any given study.31 The frequency of significant publications linking BMI with 
the gut microbiome by sequencing measures conducted on fecal samples suggests that there are 
meaningful BMI-related predictors of the gut microbiota. However, the inter-population 
generalizability with current methods remains extremely low due to variability from other 
predictors such as the diet.32 The relationship between obesity and the gut microbiome may be 
bidirectional as well, meaning that the gut microbiome is both altered by obesity and contributes 
to the pathology of obesity.23 The strongest evidence that a link exists between BMI and the gut 
microbiota comes from 2 studies by the Turnbaugh lab which show that the gut microbiome from 
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genetic ob/ob, leptin deficient, and diet-inducted obese mice induce obesity in lean germ free 
gnotobiotic mice when transplanted.33,34 
 
 
Background Figure 1. Conserved and variable aspects of the human microbiome, from the 
Human Microbiome Project, 2007.35 
Recently, it has been shown that the intestinal microbiota control key mechanisms 
necessary for proper immune responses.36,37 Since obesity has been shown to elicit substantial 
alterations to the gut microbiota and the gut microbiota has been shown to contribute to the 
pathology of obesity,38 further research is needed to determine if alterations associated with BMI 
impact the immune response to infectious diseases. Since our gut microbiota and immune systems 
evolve together with age, it is intuitive that alterations to the gut microbiota could affect the 
function of the immune system.39 On the topic of vaccine response specifically, Zimmerman et al. 
found that the phyla Firmicutes and Actinobacteria are associated with heightened cellular and 
humoral vaccine response across several types of vaccinations (oral and parenteral).37 They also 
found that Bacteroidetes (oral vaccines) and Proteobacteria (oral and parenteral vaccines) were 
associated with lower responses.37 Oh. et al. found strong evidence of the role of the gut microbiota 
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in the immune response to the influenza vaccination.36 They found that toll-like receptor 5 (TLR5) 
has a crucial role in the immune response to the TIV. TLR5 is responsible for the sensing of 
flagellin, a protein on flagellated bacteria and plays a role in influenza specific plasma cell 
differentiation.36 TLR5 directly stimulates lymph node macrophages to produce plasma cell 
growth factors. 
These studies show that the gut microbiota is closely related to the immune response to 
vaccinations and infectious diseases. There are an innumerable number of possible mechanisms 
through which the gut microbiota can affect the immune system. Obesity as a predictor of the gut 
microbiome therefore, needs to be investigated in the context of the influenza vaccination to 
elucidate future directions of research into mechanism discovery into why the TIV fails in obese 
individuals.  
There are many studies investigating these relationships in mice, but there is a lack of 
population-based human data that integrate data on obesity, the intestinal microbiota, and vaccine 
response in the same study. Therefore, for the first time this study will link BMI, the gut 
microbiota, and the immune response to the influenza vaccination. The goal of this research is to 
provide future directions for TIV research in obesity by taking a non-mechanistic correlative 
bioinformatics approach to these interactions. My hypothesis is that BMI and the gut microbiota 
will be correlated at the phylum level, and that the gut microbiota will be correlated in turn with 
impairment of the cellular response to the influenza vaccination. I propose 3 specific aims to test 
this hypothesis: 
Aim 1: Determine if gut microbial composition is associated with body mass index. 
Hypothesis: The relative abundance of the phylum Firmicutes is positively associated with BMI 
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and phylum Bacteroidetes is inversely associated with BMI. Obesity is known to cause alterations 
to the gut microbial communities. 
Aim 2: Determine if gut microbiota phylum level relative abundance is associated 
with the T and B cell response to the influenza vaccination. Hypothesis: T and Bcells from 
obese adults, upon stimulation with influenza vaccine strains, will be less activated and less 
functional compared with healthy weight adults.15 Furthermore, this impairment will be associated 
with increased Firmicutes and decreased Bacteroidetes species seen with increasing BMI.37  
Aim 3: Determine if there is a correlation between the gut microbiota, obesity, and 
the immune response to the influenza vaccination. Hypothesis: We expect that due to the 
preponderance of evidence linking diet and obesity to the intestinal microbiota, and the intestinal 
microbiota to the immune response to vaccination, there will be overlap in certain types of bacteria. 
The phylum Firmicutes is a current focal topic of discussion as a positive mediator of immune 
response to immunization.37 As Firmicutes have been found to be of heightened abundance in 
obesity38, it is expected that this may be an intermediary phylum for a reduced vaccine response 
in obese individuals. We also expect that decreased Bacteroidetes contents at a higher BMI will 










CHAPTER II – METHODS, RESULTS, DISCUSSION 
Methods 
Study Design and Participants 
Participants were recruited from the ongoing annual prospective observational cohort study 
on influenza vaccination carried out at the University of North Carolina at Chapel Hill Family 
Medicine Center conducted by the Beck Lab during the 2014-2015 influenza vaccine year. The 
Family Medicine Center is an academic outpatient primary care facility in Chapel Hill, North 
Carolina. Recruitment criteria for this study were adults 18 years of age or older receiving the 
seasonal trivalent inactivated influenza vaccination (TIV).  
Exclusion criteria were immunosuppressive diseases such as HIV, use of 
immunomodulatory or immunosuppressive drugs, acute febrile illness, history of Guillain-Barre 
syndrome, use of theophylline preparations, or use of warfarin.2 All recruitment, vaccine 
administration, sample collection, and personal information collection procedures were approved 
by the Biomedical Institutional Review Board of the University of North Carolina at Chapel Hill. 
A total of 3,304 patients were recruited to this flu study between 2009 and 2017. At 
enrollment, informed consent, height, weight, and a pre-vaccination serum sample were collected 
from each participant. Additional demographic information was obtained from the participants’ 
UNC Health Care online medical records. Upon recruitment, one dose of TIV was administered 
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and the first blood draw was collected. After 30 days post-vaccination, the second blood draw was 
conducted. See subsequent Vaccination and Blood Draw section for the clinical protocol.  
A group of 17 participants were recruited from the flu study to participate in this sub-study 
during the 2014-2015 year of the study. This group of participants were selected from the cohort 
participants for relative equality by race, gender, and obesity status. Eligibility assessment and 
recruitment was completed by phone. Study staff met eligible and interested individuals at the 
UNC Family Medicine Center, where participants were consented and provided with instructions 
and materials for the at-home stool collection. Upon completion of their sample collection, 
participants called and dropped samples off at the UNC Family Medicine Center.  
 These participants were asked to provide a one-time stool. Race was dichotomized into 
African American and Caucasian. The study group was comprised 10 females (58.8% female), 10 
African-Americans, (58.8% African American), 12 obese individuals, 1 non-obese overweight 
individual, and 4 lean individuals (70.6% obese). All participants had a serum sample used for 
analysis of antibody response, and a second second sample for perpipheral blood mononuclear cell 
isolation. A small 7-person group matched by age, race, and BMI was selected for exploratory T 
cell analysis on their blood samples. This T cell subgroup was comprised of 6 obese individuals 
(85.7% obese), 6 males (85.7% male), and 4 African American individuals (57.1% African 
American). Demographic information can be found in Table 1 and Table 2. 
Participant 
characteristic 
All participants T Cell Analysis Sub 
Group 
Age, mean(SD) 50 (6.4370) 46.39 (6.973) 




Gender, % 58.8% female 14.3% female 
BMI, mean(SD) 32.25 (6.419) 34.01 (5.558) 
Table 1. Descriptive statistics of demographic information for subjects selected from ongoing 
annual prospective observational cohort study in influenza vaccination carried out at the University 
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of North Carolina at Chapel Hill Family Medicine Center conducted by the Beck Lab during the 
















06_2104 s12 50 Female African 
American 
41.4 No 
06_2133 s17 52.3 Female Caucasian 34.6 No 
06_2135 s1 48.4 Female Caucasian 30.7 No 
06_2152 s14 35.5 Female Caucasian 20.8 No 
06_2157 s5 46.7 Female Caucasian 37.7 No 
06_2180 s13 42.8 Male African 
American 
37.9 No 
06_2192 s15 55.1 Male African 
American 
32.6 Yes 
06_2226 s8 43 Male Caucasian 41.0 Yes 
06_2229 s2 52.2 Female African 
American 
28.1 No 
06_2230 s11 56.9 Female African 
American 
31.6 No 
06_2235 s9 42.2 Female African 
American 
22.6 No 
06_2242 s10 34.8 Female African 
American 
37.9 Yes 
06_2243 s6 41.2 Female African 
American 
24.7 No 
06_2278 s16 47.7 Male African 
American 
23.3 Yes 
06_2325 s3 51 Male African 
American 
31.5 Yes 
06_2392 s4 51.4 Male Caucasian 35.0 Yes 
06_2469 s7 41.7 Male Caucasian 32.8 Yes 
Table 2. Demographic information for subjects selected from ongoing annual prospective 
observational cohort study in influenza vaccination carried out at the University of North Carolina 
at Chapel Hill Family Medicine Center conducted by the Beck Lab during the 2014-2015 influenza 






Vaccination and Blood Draw 
One dose of the 2014-2015 trivalent inactivated influenza vaccine (0.5 ml Fluvirin; 
Novartis Vaccines and Diagnostics Limited, Basel, Switzerland) containing A/California/07/2009 
H1N1, A/Texas/50/2012 H3N2, and B/Massachusetts/02/2012, was administered intramuscularly 
to the deltoid muscle, using a 1.5-inch needle.2 In addition to a pre-vaccination blood draw 
collected during the vaccination visit, the subjects were asked to return for a one-time blood draw 
one month (26-35 days) post-vaccination.2 Vaccination of participants took place from September 
15, 2014 to October 28, 2014. Serum and peripheral blood mononuclear cells (PBMCs) were 
collected from each patient. Serum samples were stored at -80oC, and PBMCs were stored in liquid 
nitrogen until analyzed.  
PBMC Stimulation 
PBMCs were be thawed and cultured with Influenza A 2009 California pandemic strain, 
which was represented in the vaccine given to the study participants. Cells were cultured for 72 
hours with stimulation by 20 µL of 5 µg protein/µL stock of live pandemic 2009 California 
Influenza A H1N1 virus (multiplicity of infection ~1) at 37oC in 5% CO2. PMBC supernates were 
collected after 66 hours in culture and replaced with GolgiPlug (BD BioSciences) containing 
media.  
T cell response using flow cytometry 
The flow cytometry protocol has been established previously in the Beck Lab for the 
analysis of PBMCs, as reported in Paich et al.18 Following 3 days of culture, cells were stained 
with human fluorochrome-conjugated human antibodies for the following markers of T cell 
activation and function: CD3, CD4, CD8, CD28, CD69, IFN-γ, and GrB. The specific PBMC 
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fluorescence-activated cell sorter (FACS) staining fluorochromes for each different cell marker 
are shown in Table 3. Sample data were acquired using an Attune NxT (Thermo Fisher) flow 
cytometer and were analyzed with FlowJo (FlowJo LLC) analysis software and R.18 CD3+CD4+ 
and CD3+CD8+ cells were selected by gating the forward vs side scatter plot of the PBMC 
population.18 Cells were then analyzed for surface expression of CD69, and for intracellular 
expression of IFN-γ and GrB.18 An example gating strategy can be found in Figure 1. All marker-
specific antibodies were titered to determine the most appropriate concentration to use in the flow 
cytometry panel.18 Single-stained cells and single-stained compensation beads for every 
fluorochrome were used as compensation controls. Autofluorescence was calculated and included 
in the compensation adjustments. 
 








Zombie  Aqua Extracellular 405nm 512nm 405nm 512/25 
CD3 AF700 Extracellular 637nm 720nm 637nm 720/30 
CD8 AF594 Extracellular 561nm 620nm 561nm 620/15 
CD4 PacificBlue Extracellular 405nm 550nm 405nm 440/50 
CD28 AF488 Extracellular 488nm 520nm 488nm 530/30 
CD69 BV711 Extracellular 405nm 780nm 405nm 710/50 
GrB APC Intracellular 637nm 654nm 637nm 670/14 
IFN-γ PE Intracellular 570nm 578nm 570nm 585/16 
Table 3. T cell functional panel: fluorochrome-conjugated antibodies used for T cell FACS panel 





Figure 1. PBMC gating strategy for flow cytometry identification of T cell functionality. 
 
Antibody response 
Serum samples were tested for vaccine hemagglutination inhibition (HAI) titers, as well as 
influenza specific relative levels of total IgG, IgG1, IgG2 and IgG3 using ELISA. The Beck Lab 
has previously reported protocols for the HAI assay, as seen in Paich et al.18 The HAI assays were 
done to characterize the level of antibodies specific to the California pandemic H1N1 (pH1N1) 
influenza virus.18 Serum from each sample was treated with receptor destroying enzyme overnight, 
followed by incubation at 56oC for 1 hour, and diluted with phosphate-buffered saline (PBS).18 
Sera were then incubated in duplicate with A/California/4/2009 (H1N1) briefly at room 
temperature and turkey red blood cells were added.18 The titer was defined as the reciprocal of the 
dilution of the last well. 
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The antibodies IgG1 (immunoglobulin 1), IgG2, IgG3, and total IgG was measured using 
enzyme-linked immunosorbent assay (ELISA). The samples were diluted and incubated in buffer 
in a pre-coated Falcon 96 well plate at 37oC for 2 hours. Anti IgG1, anti IgG2, and anti IgG3 
conjugated to horseradish peroxidase was added to each well and incubated for 1 hour at 37oC. 
The plates were then washed with PBSt, and TMB substrate solution mix was added. PBSt is 
standard-phosphate-buffered saline (PBS) with Tween, a nonionic detergent emulsifier used to 
disrupt the plasma membrane for protein release. 3,3',5,5'-Tetramethylbenzidine (TMB) substrate 
solution is a visualizing agent in ELISA that detects horseradish peroxidase and changes from blue 
to yellow in response to low pH. After a brief final room temperature incubation, the reaction was 
stopped with 2M Sulfuric Acid. The absorbance of each well was measured at 450nm to 
characterize the amount of antibody present. 
Stool Sample Collection and Sequencing 
The participants in this study were requested to provide a stool sample during the 2014-
2015 flu vaccine year. After participants dropped their stool sample at the UNC Family Medicine 
Center, they were picked up by study staff and transported to the Beck lab at the UNC Chapel Hill 
for storage at -80oC. Sample analysis was completed at UNC-Charlotte under the direction of Dr. 
Jennifer Weller in conjunction with Dr. Katie Meyer at UNC Chapel Hill. A similar protocol can 
be found in the CARDIA Study manuscript by Sun et al40 published by the Meyer Lab. 
DNA was extracted from the fecal samples. Jobin Lysis buffer (600 µL) was added to 1-3 
pellets of sample and incubated at 37oC. Then 60ul of 10% SDS and 40ul of Proteinase K was 
added and the samples were incubated at 37oC. Next, 100ul of Zirconium beads (BioSpec Products, 
Inc; Cat No. 11079110z) were added and the samples were incubated at 60oC. The samples were 
then added to 700ul 2X CTAB buffer and incubated at 60oC. The supernatant was then stored in 
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760ul Isopropanol/NaOAc at -20oC. A Qiagen column (QIAamp DNA Stool Mini Kit) was used 
to purify the genomic material. An E. coli positive control (100ng of genomic DNA in 200ul of 
low-TE buffer) and a buffer negative control were incorporated at this step. A NanoDrop 2000 
machine was used to estimate the concentration and purity of the sample via 260/280 absorbance 
ratio.  
The V3/V4 hypervariable regions were amplified (primers: 341F/785R)41 and index 
primers (Nextera XT Index Primers, Index 1 N7XX0, and Index 2 S5XX) were added in two 
subsequent polymerase chain reaction (PCR) runs. Run 1 cycle protocol: (95C 3min; 25 x (95oC 
for 30 sec, 55oC for 30 sec, 72o C for 30 sec), 72oC for 5 min, 4oC hold). Run 2 cycle protocol: 
(95oC for 3min; 8 x (95oC for 30 sec, 55oC for 30 sec, 72oC for 30 sec), 72oC for 5 min, 4oC hold). 
Ampure XP Beads were used for the PCR cleanup step after both runs. The NanoDrop 2000 was 
again used to yield and purity of the DNA. The 16S ribosomal RNA (rRNA) V3/V4 hypervariable 
regions were sequenced using the Illumina MiSeq platform.   
16S raw sequence analysis 
The raw sequences were demultiplexed, denoised, and counted; and paired ends were 
merged using Quantitative Insights to Microbial Ecology (QIIME) 1.9 on the Longleaf Linux 
supercomputing cluster at University of North Carolina at Chapel Hill. The analysis was run 
through the BioLockJ pipeline which was developed by Mike Sioda and the Fodor Lab that 
incorporates QIIME 1.9 and R for the processing of operational taxonomic units (OTUs) and 
metadata analysis. BioLockJ is a tool that imports metadata files to QIIME1.9. PEAR (Paired End 
reAd mergeR) software was used to merge forward and reverse strands of paired end sequences, 
such that sequences that did not match 10 base pairs were excluded. It converts Fastq (raw 
sequences and quality) to Fasta (raw sequence only) file format using the “awk” command in 
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Linux. It then constructs the QIIME mapping file and conducts open reference OTU picking with 
the Silva database of conserved microbial 16S rRNA sequences. OTU picking was performed to 
generate abundances that corresponded to each OTU. Lastly it normalizes the data to mitigate 
differences in library sizes and generates OTU tables using R for statistical analysis. Rare / zero 
inflated taxa with zero counts greater than 25% of the sample size were removed from statistical 
consideration.  
Variable Generation 
The OTU abundances were normalized according to the methodology described in 
McCafferty et al and seen in Equation 1 below.42 The Vegan package in R was used to calculate 
the Shannon alpha diversity and richness for each individual at the phylum level. For Beta 
diversity, PCoA (principle coordinate analysis) based on a Bray Curtis dissimilarity matrix was 
generated to characterize inter-cluster variation between the groups of interest.  
 
Equation 1. Normalization equation used on OTU outputs from open-reference picking. RC 
(number of raw counts in a given OTU), n (number of sequences in a sample), N (total number of 
samples), Σx (sum of the total number of counts in the OTU table). 
 
Body mass index was calculated for each participant as weight in kilograms divided by 
height in meters-squared (kg/m2). Obesity was defined as a BMI greater than 30, overweight as a 
BMI from 25-29.9, and healthy weight as BMI of 18.5-24.9.  
Inferential analysis 
Statistics were generated using R. Spearman’s rank-order correlation was used for the 
majority of the statistical modeling due to the non-normal nature of the OTUs after normalization 
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in the small sample size. Spearman correlation with each phylum level OTU was tested for BMI, 
IgG ELISA, HAI, and T cell flow cytometry data. Spearman correlation with phylum-level 
Shannon alpha diversity and richness was tested for BMI, IgG ELISA, HAI, and T cell flow 
cytometry data. For the BMI comparison with OTU, the data was subset by gender and race to 
address confounding. For comparisons done between gender and binary obesity and Shannon alpha 
diversity, a Wilcoxon rank sum test was used to generate a p-value. A significance level of α = 
0.05 was used for these analyses. The Benjamini and Hochberg (BH) correction was used to 
generate false discovery rate (FDR) – adjusted p values as well, due to the large number of 
comparison conducted. In analyzing the adjusted p values, the significance level was increased to 
α = 0.1, because it is standard to increase the false discovery rate to 10% after FDR-adjustment. 
Bray Curtis Principle Coordinates Analysis (PCoA) were also run to analyze clustering based on 
body weight status and immune measures. Principle component analysis (PCA) was conducted as 
a second measure of clustering. PERMANOVA was not conducted due to a lack of clustering in 
the PCA. 
Results 
Interpretation of Results: A Benjamini Hochberg (BH) correction was conducted to 
mitigate the false discovery rate as mentioned previously. This was done on all Spearman 
correlation tests (rank-order) which means that the new significance level is 0.1 instead of 0.05. R 
graphics outputs contain the p value before the correction, and the corrected p values can be found 
in the plot captions. The BH correction was NOT done on on the Wilcoxon rank-sum tests due to 
the very small number of hypotheses tested using this method and the significance level remains 
at 0.05.  
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Body Mass Index Correlated with One Phylum Level OTU. The number of Firmicutes 
OTUs was significantly correlated with body mass index (p = 0.004247, R = -0.76) as seen in 
Figure 2. This was contrary to the hypothesis that Firmicutes would increase in abundance as BMI 
increased. There was no observed change in the abundance of Bacteroidetes which was contrary 
to the hypothesis that Bacteroidetes OTUs would decrease with increased BMI. No other phyla 
were significantly correlated with BMI. After subsetting the data by gender and race to account 
for multiple predictors, it was determined that Caucasian participants had the highest amount of 
correlation in this comparison (p = 0.02519, R = -0.93), and the only significant correlation of all 
4 subsets (African American p = 0.2109, R = -0.71), (male p = 0.1172, R = -0.82), (female p = 
0.3334, R = -0.60). This method of accounting for the interaction between BMI and gender was 
stringent at this small sample size. Graphical correlation plots for the subset by race are found in 
Figure 3. Graphical correlation plots for the subset by gender are found in Figure 4.  
 
Figure 2. Correlation plot between Firmicutes OTU (y axis) and body mass index (x axis). Higher 




Figure 3. Correlation plot between Firmicutes OTU (y axis) and body mass index (x axis). African 
American participants (top) and Caucasian participants (bottom). Higher BMI is correlated with a 
decrease in Firmicutes OTU found in the gut microbiota in the Caucasian subset only (p = 
0.02519). P – values pictured are unadjusted for FDR and were not used in this analysis. For the 






Figure 4. Correlation plot between Firmicutes OTU (y axis) and body mass index (x axis). Female 
participants (top) and male participants (bottom). P – values pictured are unadjusted for FDR and 




BMI Correlated with Microbial Diversity. Normalized Shannon alpha diversity was 
correlated negatively with BMI according to Spearman’s correlation (p = 0.0127, R = -0.59) such 
that Shannon alpha diversity decreases and BMI increases. Shannon alpha diversity is a measure 
of the intra-individual diversity of microbiota and accounts for differences in abundance and 
evenness. The normalized Shannon alpha diversity also differed significantly between obese and 
non-obese individuals according to a Wilcoxon Rank-sum test (p = 0.0320). There was no 
observed change, however, in richness (the sum of all OTUs in an individual) which is an 





Figure 5. Correlation plot (top) between Shannon alpha diversity and BMI (p = 0.0127). Wilcoxon 
rank sum (bottom) test comparing Shannon alpha diversity between obese and non-obese 
individuals (p = 0.0320). Both show diminishing Shannon alpha diversity of gut microbial flora 
with increased body mass. 
 
B Cell Measures of Vaccine Response Correlated with BMI. BMI correlated positively 
and significantly with post-vaccination total IgG (p = 0.01493, R = 0.67), total IgG pre:post 
vaccination ratio (p = 0.008669, R = 0.72), and total IgG pre - post difference (p = 0.008669, R = 
0.71). Correlation was also significant and positive between BMI and the post-vaccination HAI 
viral titer (p = 0.008669, R = 0.72). No other measures of IgG or HAI titers were significantly 
correlated with BMI. In all of these measures, as BMI increased so did the magnitude of the B cell 







Figure 6. (From top down): Correlation plots of BMI with post-vaccination total IgG (p = 
0.01493), pre:post vaccination total IgG ratio (p = 0.008669), pre – post vaccination total IgG 




 Firmicutes and Bacteroidetes OTUs differ with Gender. There were significant 
differences between Firmicutes (0.0811) and Bacteroidetes (0.03850) with gender as the binary 
stratification criteria. Males had lower abundance of Firmicutes and higher abundance of 
Bacteroidetes than females in the study population. No other microbial phyla had significant 
differences between genders. 
 
Figure 7. Comparison of Firmicutes (top) and Bacteroidetes (bottom) phylum OTUs between 
gender. Male participants had a lower mean abundance of Firmicutes (p = 0.02811). Female 
participants had a lower abundance of Bacteroidetes (p = 0.03850). 
 
 Some OTUs Correlated with B Cell Measures. This is a notable finding, particularly in 
the case of the phylum Firmicutes. Firmicutes, which was found to correlate significantly with 
BMI, was also significantly correlated with pre : post vaccination total IgG ratio (p = 0.01723, R 
= -0.72), pre – post vaccination total IgG difference (p = 0.01723, R = -0.70), and post vaccination 
HAI titer (p = 0.03632, R = -0.64). This is notable because it represents a phylum level link 
between body mass, the gut microbiota, and the immune response to the TIV and the influenza 
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virus. Firmicutes also showed promising association with post vaccination total IgG, post 
vaccination IgG1, and pre vaccination HAI titer, but none of these were significant (p = 0.1114, p 
= 0.1646, and p = 0.1896, respectively at α = 0.1). Significant correlation visualizations for 
Firmicutes and the B Cell parameters can be found in Figure 8. Another correlation of note was 
between the phylum Actinobacteria and pre vaccination IgG2 (p = 0.05444, R = -0.68). Though 
this is not a function of the 2014-2015 vaccine, it is also a one-year post 2013-2014 TIV 
immunization measure within the cohort. See Figure 8 for the Actinobacteria correlation plot. For 
both Firmicutes and Actinobacteria, as the OTU increased the B cell response decreased. No other 








Figure 8. (From top down) Correlation plots between Firmicutes OTU and pre : post vaccination 
total IgG ratio (p = 0.01723), pre – post vaccination total IgG difference (p = 0.01723), and post 
vaccination HAI titer (p = 0.03632). Correlation plot between Actinobacteria and pre vaccination 




 B Cell Response not Correlated with Diversity. Neither Shannon alpha diversity nor 
richness at the phylum level were associated significantly with any of the IgG or HAI titer 
measures of the B cell response to the TIV or influenza virus.  
 T Cell response not Correlated with BMI. None of the T cell parameters designated in the 
functional panel gating strategy were significantly correlated with BMI in the study population. 
 Some OTUs Correlated with T Cell Response. While the phylum Firmicutes, which is 
correlated with BMI and B cell response was not significantly correlated with the T cell response 
as measure by flow cytometry, there were three other microbial phyla that were significantly 
correlated with the T cell response in the study population. Phylum Actinobacteria was 
significantly positively correlated with the number of CD8+ cytotoxic T cells that expressed 
neither of the functional cytokines IFN-γ (interferon gamma) nor GrB (granzyme B) upon 
stimulation with influenza virus (p > 0.0001, R = 1), which are needed in response to influenza. 
Additionally, the phylum Patescibacteria was significantly negatively correlated with the number 
of CD4+ helper T cells in unstimulated PBMCs (p = 0.04905, R = -0.96). Lastly, phylum 
Verrucomicrobia was significantly correlated with the frequency of CD4+ CD28+ helper T cells 







Figure 9. Correlation plot between Actinobacteria (top) and the count of IFN-γ, GrB double-
negative CD8+ cytotoxic T cells upon activation with influenza virus (p > 0.0001). Correlation 
plot between Patescibacteria (middle) and count of CD4+ helper T cells in unstimulated PBMCs 
(p = 0.04905). Correlation plot between Verrucomicrobia (bottom) and frequency of CD4+ CD28+ 
influenza activated helper T cells expressing CD69 (p = 0.0870). 
 
 T Cell Response Correlated with Diversity. While none of the T cell parameters designated 
in the functional panel gating strategy were significantly correlated with Shannon alpha diversity 
in the study population, there were two parameters that were significantly correlated with richness. 
Richness (the sum of the OTUs within each individual) was significantly correlated with the 
frequency of CD4+ CD28+ helper T cells expressing CD69 (p = 0.04390, R = 0.95) upon activation 
with influenza virus. Richness was also significantly correlated with the number of unstimulated 
CD8+ cytotoxic helper T cells that expressed IFN-γ but not GrB (p = 0.09154, R = 0.93). As 




Figure 10. Correlation plot between richness and (top) frequency of CD4+ CD28+ helper T cells 
expressing CD69 (p = 0.04390). Correlation plot between richness and (bottom) count of 




 OTUs did not Demonstrate Significant Clustering by Demographic, Body Mass, T Cell, 
or B Cell Metadata. In both PCA (principal component analysis) of variation and PCoA (principal 
coordinate analysis) of distances, we did not find any significant clustering or separation based on 
the OTUs or the metadata. In the PCA analysis, while we did observe tighter clustering in non-
obese individuals compared to obese individuals, it was not possible to prove that there was a 
difference in the clustering behavior since the lean cluster was entirely contained within the obese 
cluster at every combination of dimensional analysis we conducted. This result is intuitive because 
obesity contains more gastrointestinal disease phenotypes than being healthy weight. See Figure 
11 and 12 for PCA plots. As seen in Figure 11, there was no improvement in clustering when 
examining multiple dimensions. Therefore, a PERMANOVA would not provide substantial 
information about clustering behavior between individuals in the study. We analyzed all 
dimensions for gender and BMI (Figure 12) as well and did not find any evidence of significant 
clustering between individuals. In Figure 13 we generated a Biplot using the PCA to create a 
visualization of which phyla contributed more to which individuals in the study. In Figure 14 we 
generated a factor map as a visualization of which phyla contributed the most to the total variance 
explained in the PCA. See Figure 15 for PCoA plots. When analyzing across multiple dimensions 










Figure 11. (From top down): PCA plots visualizing dimensions 1 through 4: dimension 1 and 2 
(top), dimension 1 and 3, dimension 2 and 3, dimension 1 and 4, dimension 2 and 4, and dimension 
3 and 4 (bottom). No significant clustering occurred. Coloring by obese, lean, and overweight as 





Figure 12. PCA Plots coloring by gender (top) and BMI gradient (bottom). When analyzing 





Figure 13. Biplot where individuals are plotted as points (e.g. S11) and the phyla are plotted as 
factors on the biplot to show which phyla contribute more to which individuals. 
 
 
Figure 14. Factor map colored by contribution score for each phylum. A phylum that is closer to 
the correlation circle with a higher contribution score accounts for more of the variance explained 









Figure 15. PCoA plot coloring by obese vs non-obese individuals (top), gender (middle), and 
median-stratified post-vaccination total IgG (bottom). None of the PCoA analyses yielded 
significant clustering after analyzing all dimensions. 
 
Discussion 
 The tests in my analysis are designed to generate future hypotheses. In the bioinformatics 
analysis I conducted above, all tests are associative and therefore cannot prove mechanistic 
causation of any kind. This study offers the first reports of BMI – associated gut microbiota 
differences being associated with the humoral response to the influenza vaccination, which is 
promising for future studies.  
BMI and the Immune Response to the TIV: 
BMI correlated significantly with post-vaccination total IgG (p = 0.01493), total IgG 
pre:post vaccination ratio (p = 0.008669), and total IgG pre - post difference (p = 0.008669). 
Correlation was also significant between BMI and the post-vaccination HAI viral titer (p = 
0.008669). This positive correlation is counterintuitive because IgG and HAI titer responses post 
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vaccination are measures of protection against the influenza virus. It is not true the obese 
individuals are more protected against the flu. Previous research in the Beck lab has shown B cell 
functionality to drop off significantly between one month and one-year post vaccination in obese 
individuals compared to healthy weight individuals. This means that obese individuals cannot 
sustain an influenza antibody response that lasts as long as healthy-weight individuals do after the 
TIV. Those with a diminished antibody response are more susceptible to infection and severe 
outcomes of infection.  
Studies in Beck Lab have shown the adaptive immune system is impaired in response to 
influenza vaccination and infection. Despite vaccination, obese individuals are two times as likely 
to have influenza or influenza like illness.2 Further investigation identified T cells in obese 
individuals as the potential cause of impaired immune response. T cells from obese individuals 
express lower levels of activation markers CD69 and CD28 and lower levels of functional markers 
IFN-γ and Granzyme B.  
 None of the T cell parameters designated in the functional panel in this study were 
significantly correlated with BMI in the study population. This also contrasts previous research 
done in our lab which found notable impairment of T cell functional and metabolic function. This 
discrepancy is likely due to the small sample size of this investigation which could have made this 
study underpowered to detect smaller differences in flow cytometry data. Overall, my data suggest 
that the investigation should continue into obesity-related impairments of B cells and plasma cells.  
BMI and the Gut Microbiota:  
BMI was found to correlate only one phylum level OTU in the gut microbiota: Firmicutes. 
Firmicutes OTUs were significantly correlated with body mass index (p = 0.004247). In Figure 2 
50	
	
it is clear that amount of Firmicutes diminishes with increasing BMI. This contrasted with the 
hypothesis that the amount of Firmicutes would increase with BMI. It also contrasted the 
hypothesis that Bacteroidetes would diminish significantly with increasing BMI. 
Normalized Shannon alpha diversity was correlated negatively with BMI according to 
Spearman’s correlation (p = 0.0127) such that Shannon alpha diversity decreases and BMI 
increases. Shannon alpha diversity is a measure of the intra-individual diversity of microbiota and 
accounts for differences in abundance and evenness. The normalized Shannon alpha diversity also 
differed significantly between obese and non-obese individuals according to a Wilcoxon Rank-
sum test (p = 0.320). This contrasted the previous finding that obesity is associated with lower 
Shannon alpha diversity.  
These results appear to further support the idea that according to the standard analytical 
and sequencing methods, there is an extreme lack of consistency in findings of association between 
BMI and any measures of the gut microbiota. This phenomenon could indicate a need for the 
development of smarter bioinformatics tools and more affordable and precise approaches to 
sequencing the gut microbiome. However, it could also indicate simply that obesity is highly 
variable in humans, and therefore has effects on the gut microbiota that are diverse in nature. 
Richness (the sum of the OTUs within each individual) was significantly correlated with 
the frequency of CD4+ CD28+ helper T cells expressing CD69 (p = 0.04390) upon activation with 
influenza virus. Richness was also significantly correlated with the number of unstimulated CD8+ 
cytotoxic helper T cells that expressed IFN-γ but not GrB (p = 0.09154). As richness increases, 
both of these parameters increase. This means that Th cells and CTLs were more activated in 
individuals who have a more “rich” gut microbiota. The cumulative number of OTU’s is not a 
perfect measure of the amount of organisms in one’s gut microbiota, it is simply a measure of how 
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many recurring 97% matched 16S rRNA sequences were observed. However, this result could 
imply that in individuals with higher richness, more bacterial fragments and products could be 
permeating the gut, which could be caused by multiple potential factors. This would then result 
increased inflammation by causing visceral immune cells to secrete more pro-inflammatory 
cytokines. Richness was not found to be a function of BMI in this analysis however, but this should 
also be a direction for future research. 
The Gut Microbiota and the Immune Response to TIV: 
 It is hypothesized that high fat diets cause increased intestinal permeability and increased 
translocation of bacterial components and their products which increases inflammation in the 
visceral adipose tissue.23 However, the mechanistic connections between specific gut microbiota 
and the immune components that are affected by the gut are poorly understood.39 
 The most notable finding of this study is in the case of the phylum Firmicutes. Firmicutes, 
which was found to correlate significantly with BMI, was also significantly correlated with pre : 
post vaccination total IgG ratio (p = 0.01723), pre – post vaccination total IgG difference (p = 
0.01723), and post vaccination HAI titer (p = 0.03632). This is significant because it represents a 
phylum level link between body mass, the gut microbiota, and the immune response to the TIV 
and the influenza virus. Firmicutes also showed promising association with post vaccination total 
IgG, post vaccination IgG1, and pre vaccination HAI titer, that might be significant with a more 
adequately powered investigation. Another correlation of note was between the phylum 
Actinobacteria and pre vaccination IgG2 (p = 0.05444). Though the pre-vaccination IgG ELISA 
is not a result of the 2014-2015 vaccine, it is a measure of one-year post 2013-2014 TIV 
immunization response due to annual vaccination in our cohort. As Actinobacteria increased the 
B cell response decreased.  
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 In the relationship between BMI, the gut microbiota at the phylum level, and the humoral 
antibody response to the trivalent influenza vaccination, it is true that three factors are significantly 
correlated with each other. This data shows that there is a need for future investigation into the 
causal directionality of this interaction. This could be achieved by the use of a gnotobiotic mouse 
model where fecal samples from lean and obese individuals are transplanted and the mouse is 
analyzed for its immune response to influenza virus or the TIV immunization.  
While the phylum Firmicutes, which is correlated with BMI and B cell response was not 
significantly correlated with the T cell response measured by flow cytometry, there were three 
other microbial phyla that were significantly correlated with the T cell response in the study 
population. Phylum Actinobacteria was significantly positively correlated with the number of 
CD8+ cytotoxic T cells that expressed neither IFN-γ (interferon gamma) nor GrB (granzyme B) 
upon stimulation with influenza virus (p > 0.0001). This implies that in our study population, gut 
microbiota states associated with higher OTUs of Actinobacteria are correlated with reduced 
expression of these functional cytokines that are necessary in the response to influenza virus. 
Additionally, the phylum Patescibacteria was significantly negatively correlated with the number 
of CD4+ helper T cells in unstimulated PBMCs (p = 0.04905). Lastly, phylum Verrucomicrobia 
was significantly correlated with the frequency of CD4+ CD28+ helper T cells expressing CD69 
upon activation with influenza virus (p = 0.0870).  
This means that higher Actinobacteria was correlated with CTLs that were either less active 
functionally upon stimulation. This means that future studies should incorporate a more intensive 
flow panel that includes more functional markers and possibly a metabolic panel as well. These 
other findings with Patescibacteria and Verrucomicrobia also suggest that there is a higher baseline 
level of Th activation with greater relative abundance of these OTUs.   
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Conclusion and Other Future Directions: 
 This computational analysis serves the purpose of drawing attention to the gut microbiota 
as a potential mechanism through which BMI has effects on the immune response to influenza and 
the TIV. Strong preliminary evidence was found linking BMI, Firmicutes, and the antibody 
response to the 2014-2015 TIV immunization. Future analysis will be conducted on the order, 
class, and genus levels to elucidate greater specificity in this relationship. This study should be 
repeated with a larger sample size to gain sufficient power to detect smaller changes than our 
bioinformatics methods were capable of recognizing. Larger sample size will also allow for a more 
probable recognition of clustering, as a 17 participant study must have drastic separation of 
clustering by OTUs and metadata in order to detect a difference. Shotgun sequencing of whole 
genome would allow insights into the virome as well which would result in more comprehensive 
study. Gnotobiotic mice are the most important tool going forward in this question, as it would 
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